
Tatva Chintan Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 2
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- Steady improvement expected over coming quarters with favorable product mix driving growth.
- Revenue grew 29% YoY to ₹1,144 million in Q1 FY2024; EBITDA up 40% YoY, indicating strong profitability.
- New product commercialization, especially in pharma and agro intermediates, expected to start contributing from Q4 FY2024 and early 2025.
- Energy storage/electrolyte salts segment to see strong growth with four customers engaged; key turning point expected in calendar year 2025.
- Flame retardants segment to stabilize with production starting September 2023; revenue guidance of ₹25-40 crore for current fiscal maintained.
- Capacity utilization expected to ramp up to ~80-85% in expanded Dahej facility by next financial year supporting volume growth.
- QIP funding to support next phase of expansion, target increasing capacity and product pipeline.
- Anticipated gross margin normalization and better pricing to sustain profitability.
- SDA segment demand expected to ramp up strongly by end 2023, aiding revenue growth.
See what Tatva Chintan management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Tatva Chintan Pharma Chem Limited is in the process of raising funds amounting to Rs. 200 crore through a Qualified Institutions Placement (QIP), which involves issuing new shares, leading to capital infusion into the company.
- The QIP will likely reduce promoter stake below 75%, aligning with SEBI guidelines.
- The funds are intended for the next phase of expansion, including development on newly acquired land awaiting environmental clearance.
- The company has already utilized approximately 97% of net proceeds from an earlier fundraising totaling Rs. 2072.81 million.
- No specific mention of new debt fundraising was reported in the most recent call; however, interest costs remain high due to increased benchmark rates, with the last scheduled repayment of existing term loans in Q1 of next year.
See what Tatva Chintan management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is raising approximately Rs. 200 crore through a Qualified Institutional Placement (QIP) to fund the next phase of expansion.
- Proceeds will be used for the development of a new piece of land bought in 2021, which is on the verge of receiving environmental clearance (possibly by August or soon after).
- The company expects to reach about 80-85% utilization of the newly expanded Dahej facility in the next financial year and is planning further expansion.
- The Rs. 150 crore expanded Dahej plant's commercial production has commenced, with expectations for higher utilization from December 2023.
- The capital expenditure will involve capacity enhancement particularly at Dahej and accelerating the launch of new products.
- QIP issuance will dilute promoter stake below 75%, complying with SEBI guidelines.
- Long-term focus on developing ultra-high purity products and entering new segments such as semiconductor materials and electrolyte salts for energy storage systems.
Track Tatva Chintan — get its next earnings analysis in your feed
How does Tatva Chintan rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Tatva Chintan rank in Chemicals & Petrochemicals?
Compare Tatva Chintan against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…